#London #United Kingdom #Virax Biolabs #ImmuneSelect #Tebubio

Virax Biolabs and Tebubio: A Game-Changing Distribution Partnership

Virax Biolabs Group Limited, listed on NASDAQ as VRAX, has made headlines with its latest agreement with French company Tebubio, a collaboration poised to significantly boost the accessibility of Virax's ImmuneSelect product line across key European markets, including the European Union, Norway, and Switzerland.

The Significance of This Partnership

In a recent press release, James Foster, the CEO of Virax, expressed enthusiasm over the agreement, emphasizing its potential to enhance the reach of ImmuneSelect within essential life science institutions in Europe. This initiative aligns with the company's mission to innovate and improve immune profiling technologies, a growing need in understanding immune health _particularly_ in the wake of global health challenges prompted by viral diseases.

Romain Cordonnier-Goulay, Chief Scientific Officer of Tebubio, echoed the sentiments, noting that their established distribution networks throughout Europe will further facilitate the provision of ImmuneSelect products, making them more available for researchers engaged in critical scientific inquiries.

Understanding ImmuneSelect

ImmuneSelect is a carefully curated line of research products developed by Virax that focuses on the exploration of adaptive immunity. While these products are designed specifically for research and investigative purposes, they play a pivotal role in studying the immune response, particularly for conditions related to viral infections. The offerings feature peptide pools that target various pathogens such as SARS-CoV-2, Lyme Disease, and Epstein-Barr Virus, among others, and are continuously updated to include new and relevant antigens.

One of the standout features of ImmuneSelect is its affordability and compatibility with standard laboratory equipment. Researchers can utilize these products across various applications, including Flow Cytometry, ELISA, and other immunological assays. This aligns with the primary goal of providing comprehensive solutions that meet the evolving demands of the life sciences sector.

The Future of Immune Profiling Technologies

Virax Biolabs is committed not only to enhancing their product lineup but also to pioneering T-cell-based test technologies. These innovations aim to empower researchers and healthcare professionals in diagnosing and treating conditions associated with viral infections, including Long COVID—an area of increasing concern in the medical community.

With these ambitious goals, the partnership with Tebubio marks a significant step towards realizing the potential of immune profiling technologies in the broader biomedical landscape, addressing crucial gaps in immune health analysis.

For more insights and updates about Virax, visit their official website at Virax Biolabs. Similarly, learn more about Tebubio and their offerings at Tebubio.

Conclusion

As the landscape of biomedical research continues to evolve, partnerships like that of Virax Biolabs and Tebubio will prove indispensable in driving innovation and accessibility to critical research tools. With the global demand for comprehensive immune health insights on the rise, this collaboration could set a precedent for future ventures in the life sciences sector.

• ---